RU2178307C2 - Производные ов-протеина - Google Patents

Производные ов-протеина Download PDF

Info

Publication number
RU2178307C2
RU2178307C2 RU98113706/14A RU98113706A RU2178307C2 RU 2178307 C2 RU2178307 C2 RU 2178307C2 RU 98113706/14 A RU98113706/14 A RU 98113706/14A RU 98113706 A RU98113706 A RU 98113706A RU 2178307 C2 RU2178307 C2 RU 2178307C2
Authority
RU
Russia
Prior art keywords
protein
immunoglobulin
igg
derivative
native
Prior art date
Application number
RU98113706/14A
Other languages
English (en)
Russian (ru)
Other versions
RU98113706A (ru
Inventor
Совадж Фредерик Дзей Де
Нанси Левин
Ричард Л. ВАНДЛЕН
Original Assignee
Джинентех Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джинентех Инк. filed Critical Джинентех Инк.
Publication of RU98113706A publication Critical patent/RU98113706A/ru
Application granted granted Critical
Publication of RU2178307C2 publication Critical patent/RU2178307C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Emergency Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU98113706/14A 1995-12-27 1996-12-19 Производные ов-протеина RU2178307C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57949495A 1995-12-27 1995-12-27
US08/579494 1995-12-27
US66718496A 1996-06-20 1996-06-20
US08/667184 1996-06-20

Publications (2)

Publication Number Publication Date
RU98113706A RU98113706A (ru) 2000-05-20
RU2178307C2 true RU2178307C2 (ru) 2002-01-20

Family

ID=27077779

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98113706/14A RU2178307C2 (ru) 1995-12-27 1996-12-19 Производные ов-протеина

Country Status (14)

Country Link
EP (1) EP0870026B1 (cg-RX-API-DMAC7.html)
JP (1) JP4037905B2 (cg-RX-API-DMAC7.html)
CN (1) CN1154726C (cg-RX-API-DMAC7.html)
AT (1) ATE267255T1 (cg-RX-API-DMAC7.html)
AU (1) AU1520097A (cg-RX-API-DMAC7.html)
BR (1) BR9612359A (cg-RX-API-DMAC7.html)
CA (1) CA2238307A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ9802013A3 (cg-RX-API-DMAC7.html)
DE (1) DE69632546T2 (cg-RX-API-DMAC7.html)
IL (1) IL124831A0 (cg-RX-API-DMAC7.html)
MX (1) MX9804687A (cg-RX-API-DMAC7.html)
NZ (1) NZ326592A (cg-RX-API-DMAC7.html)
RU (1) RU2178307C2 (cg-RX-API-DMAC7.html)
WO (1) WO1997024440A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2341534C2 (ru) * 2004-03-18 2008-12-20 СДж БИОМЕД ИНК. Иммуногенный гибридный полипептид против ожирения и вакцинная композиция на его основе
RU2352583C2 (ru) * 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
CA2236163A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
EP1835030A1 (en) * 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods
AU7132798A (en) * 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
AU2002300605B8 (en) * 1997-04-17 2006-02-09 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
ATE417068T1 (de) 1998-04-23 2008-12-15 Ajinomoto Kk Stoff mit antithrombotischer aktivität und verfahren zur bestimmung von glycokallidin
US6492138B1 (en) 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
EP1294401B1 (en) 2000-06-29 2007-08-01 EMD Lexigen Research Center Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
AU2002252035A1 (en) 2001-02-21 2002-09-12 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
CN1330664C (zh) 2001-03-07 2007-08-08 默克专利有限公司 用于含杂合同种型抗体部分的蛋白质的表达技术
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
MXPA05006384A (es) 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
KR20050086948A (ko) 2002-12-27 2005-08-30 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US7589179B2 (en) 2004-12-09 2009-09-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
JP5622720B2 (ja) 2008-05-21 2014-11-12 ニューロテスインコーポレイテッド 神経原繊維変化に関連する進行性認知障害の治療方法
JP2012508242A (ja) 2008-11-04 2012-04-05 ニコラオス テザプシディス 神経原線維のもつれ及びアミロイドβの蓄積に起因する進行性認知機能障害を治療するためのレプチン組成物及び方法
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
CN104147596A (zh) * 2013-05-14 2014-11-19 李荣秀 生物药非共价结合聚合物延长治疗浓度的方法及用途
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zhang V. et al. Positional Cloning of the Mouse Obese Gene and its Homan Gomologue. Nature.- V372, 1994, р.425-432. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2352583C2 (ru) * 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
RU2356909C2 (ru) * 2003-11-13 2009-05-27 Ханми Фарм. Инд. Ко., Лтд. Белковый комплекс, полученный с использованием фрагмента иммуноглобулина, и способ получения такого комплекса
RU2341534C2 (ru) * 2004-03-18 2008-12-20 СДж БИОМЕД ИНК. Иммуногенный гибридный полипептид против ожирения и вакцинная композиция на его основе

Also Published As

Publication number Publication date
BR9612359A (pt) 1999-07-13
CN1154726C (zh) 2004-06-23
NZ326592A (en) 2001-05-25
ATE267255T1 (de) 2004-06-15
JP2000504210A (ja) 2000-04-11
IL124831A0 (en) 1999-01-26
CN1205738A (zh) 1999-01-20
EP0870026B1 (en) 2004-05-19
CZ9802013A3 (cs) 1998-09-16
WO1997024440A1 (en) 1997-07-10
AU1520097A (en) 1997-07-28
JP4037905B2 (ja) 2008-01-23
EP0870026A1 (en) 1998-10-14
CA2238307A1 (en) 1997-07-10
DE69632546D1 (de) 2004-06-24
DE69632546T2 (de) 2005-06-30
MX9804687A (es) 1998-10-31

Similar Documents

Publication Publication Date Title
RU2178307C2 (ru) Производные ов-протеина
US7070959B1 (en) Modified chimeric polypeptides with improved pharmacokinetic properties
EP2507267B1 (en) Compositions and methods for increasing serum half-life of fc fusion proteins
EP1330260B1 (en) Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia
US6620413B1 (en) OB protein-polymer chimeras
KR100545720B1 (ko) 당화된 면역글로불린 및 이를 포함하는 면역접합체
US20070100133A1 (en) Erythropoietic compounds
US20050158831A1 (en) Multimeric fusion proteins of TNF superfamily ligands
EP1183353A1 (en) Modified chimeric polypeptides with improved pharmacokinetic properties
JP2012530493A (ja) キメラポリペプチドおよびその使用
US20180280474A1 (en) Treatment of bile acid disorders
JP7173866B2 (ja) コンジュゲートされたｃ１エステラーゼインヒビター及びその使用
US20060205660A1 (en) OB protein-immunoglobulin chimeras
HK1261372A1 (en) Conjugated c1 esterase inhibitor and uses thereof
AU1829101A (en) OB protein derivatives having prolonged half-life